Assetmark Inc. increased its holdings in shares of Guardant Health, Inc. (NASDAQ: GH) by 18,838.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,257 shares of the company's stock after acquiring an additional 13,187 shares during the period. Assetmark Inc.'s holdings in

Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Guardant Health (GH) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.62 per share a year ago.

Guru Stock PicksLi Lu has made the following transactions:Sold out in SOCNew position in CROXStock News Stocks slip, private credit hit, oil climbs: Blue Owl Ca

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an increase of 39%, driven by: Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests.

Guardant Health, Inc. (NASDAQ: GH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twenty-three research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twenty-one have given a buy recommendation

IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Walmart, Guardant Health and Quanta Services. Check out our daily newsletter!

Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March PALO ALTO, Calif., Feb. 12, 2026 /PRNewswire/ -- Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of its Community Colorectal Cancer Screening Grant Program, designed to support community-led efforts to expand access to colorectal cancer screening throughout March.

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.